High Court Won't Hear Orexigen Securities Fraud Suit
The U.S. Supreme Court declined on Monday to hear a challenge to a Ninth Circuit ruling that biotechnology company Orexigen had a duty to warn investors when new information about a...To view the full article, register now.
Already a subscriber? Click here to view full article